BBA
ACRS icon

Baader Bank Aktiengesellschaft’s Aclaris Therapeutics ACRS Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,466
Closed -$9.38K – 441
2024
Q2 		$9.38K Buy
+10,466
New +$12.3K ﹤0.01% 392

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baader Bank Aktiengesellschaft's ACRS Position: Q3 2024 in Review

Baader Bank Aktiengesellschaft sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 10,466 shares — an estimated $9.38K sold.

Baader Bank Aktiengesellschaft first reported a position in ACRS in Q2 2024 and held it in 1 quarter. The position peaked at $9.38K in Q2 2024. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • Baader Bank Aktiengesellschaft reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 10,466 Aclaris Therapeutics shares in Q3 2024, an estimated $9.38K.
  • Baader Bank Aktiengesellschaft first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Aclaris Therapeutics position peaked at $9.38K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q3 2024, filed 29 Oct 2024.